Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

966 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB. Veale DJ, et al. Among authors: hodge j. Rheumatology (Oxford). 2019 Feb 1;58(2):197-205. doi: 10.1093/rheumatology/key070. Rheumatology (Oxford). 2019. PMID: 29618084 Free PMC article. Review.
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, Biswas P, Lazariciu I, Hazra A, Clark JD, Hodge J, Wang L, Choy E. van Vollenhoven R, et al. Among authors: hodge j. Arthritis Rheumatol. 2019 May;71(5):685-695. doi: 10.1002/art.40780. Epub 2019 Apr 2. Arthritis Rheumatol. 2019. PMID: 30427585 Free PMC article.
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, Stempora L, Hammond C, Wouters A, Mojcik CF, Cheng J, Collinge M, Jesson MI, Hazra A, Biswas P, Lan S, Clark JD, Hodge JA. Weinhold KJ, et al. Among authors: hodge ja. Clin Immunol. 2018 Jun;191:10-20. doi: 10.1016/j.clim.2018.03.002. Epub 2018 Mar 5. Clin Immunol. 2018. PMID: 29518577 Free PMC article. Clinical Trial.
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS. Boyle DL, et al. Among authors: hodge j. Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028. Epub 2014 Nov 14. Ann Rheum Dis. 2015. PMID: 25398374 Free PMC article. Clinical Trial.
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. Winthrop KL, et al. Among authors: hodge j. Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20. Ann Rheum Dis. 2016. PMID: 25795907 Free PMC article. Clinical Trial.
Appraisal of the clinical value of serotoninergic drugs.
Munro JF, Scott C, Hodge J. Munro JF, et al. Among authors: hodge j. Am J Clin Nutr. 1992 Jan;55(1 Suppl):189S-192S. doi: 10.1093/ajcn/55.1.189s. Am J Clin Nutr. 1992. PMID: 1728833 Review.
966 results